Olmesartan-based fixed triple combinations: current opportunities for controlling uncontrolled hypertension

The article presents the provisions of current international guidelines for the treatment of hypertension, which emphasize the use of a fixed triple combination consisting of an angiotensin receptor antagonist, a dihydropyridine calcium channel blocker, and a thiazide or thiazide-like diuretic. The results of the key randomised controlled trials on the efficacy and safety of the fixed triple combination olmesartan/amlodipine/hydrochlorothiazide are presented.

References

1. A global brief on hypertension: silent killer, global public health crisis: World Health Day 2013. http://www.who.int/publications/i/item/a-global- brief-on-hypertension-silent-killer-global-publichealth-crisis-world-health-day-2013.
2. Qian J., Chen Y., Lu D. et al. (2023) The prevalence, disability-adjusted life years, and mortality of hypertensive heart disease and its attributable risk factors: results from the Global Burden Disease study 2019. Arch. Med. Sci., 19(5): 1186–1200. doi: 10.5114/aoms/169477.
3. Mishchenko L., Kolesnik T., Khomazyuk T. et al. (2022) May Measurement Month 2017-2019: an analysis of blood pressure screening results from Ukraine. Eur. Heart J. Suppl., 24(Suppl. F): F41–F44. doi: 10.1093/eurheartjsupp/suac035.
4. Kiro L., Zak M., Chernyshov O. (2023) Structure and dynamics of the course of chronic non-infectious somatic diseases in patients during war events on the territory of Ukraine. BMC Public Health, 23(1): 1464. doi: 10.1186/s12889-023-16394-0.
5. Belyi D., Nastina O., Sydorenko G. et al. (2024) State of cardiovascular system in servicemen of ukraine armed forces and emergency workers of the chornobyl accident. Comparative analysis. Probl. Radiac. Med. Radiobiol., 29: 311–326. doi: 10.33145/2304-8336-2024-29-311-326.
6. Burnier M., Azizi M., Magne J. et al. (2025) Patient perceptions, motivations and barriers to treatment adherence in hypertension: results of a questionnaire-based survey in five European countries. Blood Press, 34(1): 2513434. doi: 10.1080/08037051.2025.2513434.
7. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur. Heart J. 2024; 45(38): 3912–4018. doi: 10.1093/eurheartj/ehae178. PMID: 39929237.
8. Whelton P.K., Carey R., Aronow W. et al. (2018)2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol., 71(19): e127–e248. doi: 10.1016/j.jacc.2017.11.006.
9. Williams B., Mancia G., Spiering W. et al. (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: J. Hypertens., 36(10): 1953–2041. doi: 10.1097/HJH.0000000000001940.
10. Unger T., Borghi C., Charchar F. et al. (2020) 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 75(6): 1334–1357. doi: 10.1161/HYPERTENSIONAHA.120.15026.
11. Mancia G., Kreutz R., Brunström M. et al. (2023) 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J. Hypertens., 41(12): 1874–2071. doi: 10.1097/HJH.0000000000003480.
12. Parati G., Kjeldsen S., Coca A. et al. (2021) Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. Hypertension, 77(2): 692–705. doi: 10.1161/HYPERTENSIONAHA.120.15781.
13. Volpe M., Tocci G. (2012) Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vasc. Health Risk Manag., 8: 3710380. doi: 10.2147/VHRM.S28359.
14. Chen R., Suchard M.A., Krumholz H. et al. (2021) Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. Hypertension, 78(3): 591–603. doi: 10.1161/HYPERTENSIONAHA.120.16667.
15. Deng Z., Jiang J., Wang J. et al. (2022) Angiotensin Receptor Blockers Are Associated With a Lower Risk of Progression From Mild Cognitive Impairment to Dementia. Hypertension, 79(10): 2159–2169. doi: 10.1161/HYPERTENSIONAHA.122.19378.
16. Tiwaskar M., Mehta K., Kasture P. (2024) A Review of Olmesartan-based Therapy in Targeting Effective Blood Pressure Control and Achieving Blood Pressure Goals. J. Assoc. Physicians India, 72(3): 75–78.
17. Oparil S. (2002) Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists. J. Hum. Hypertens., 16(2): S17–S23. doi.org/10.1038/sj.jhh.1001394.
18. Zhang Z., Yang H., Guo H. (2024) Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis. Int. J. Clin. Pharm., 46(5): 1034–1043. doi: 10.1007/s11096-024-01755-5.
19. Shetty S., Bhoraskar A., Saboo B. et al. (2024) Olmesartan: 360-degree Perspectives Befitting an Angiotensin Receptor Blocker. J. Assoc. Physicians India, 72(12): 59–72. doi: 10.59556/japi.72.0780.
20. Burnier M., Redon J., Volpe M. (2023) Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations. High Blood Press Cardiovasc. Prev., 30(2): 109–121. doi: 10.1007/s40292-023-00563-8.
21. Julius S., Kjeldsen S.E., Weber M. et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 363(9426): 2022–2031. doi: 10.1016/S0140-6736(04)16451-9.
22. Oparil S., Williams D., Chrysant S. et al. (2001) Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J. Clin. Hypertens. (Greenwich), 3(5): 283–291. doi: 10.1111/j.1524-6175.2001.01136.x.
23. Punzi H.A. (2014) Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study. Ther. Adv. Cardiovasc. Dis., 8(1): 12–21. doi: 10.1177/1753944713520062.
24. Sohn I., Ihm S., Kim G. et al. (2021) Real-world evidence on the strategy of olmesartan-based triple single-pill combination in Korean hypertensive patients: a prospective, multicenter, observational study (RESOLVE-PRO). Clin. Hypertens., 27(1): 21. doi: 10.1186/s40885-021-00177-z.
25. Oh J., Kim W., Kim G. et al. (2023) Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors. Adv. Ther., 40(11): 4817–4835. doi: 10.1007/s12325-023-02632-9.
26. Weir M.R., Hsueh W.A., Nesbitt S. et al. (2011) A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. J. Clin. Hypertens. (Greenwich), 13(6): 404–412. doi: 10.1111/j.1751-7176.2011.00437.x.
27. Narita K., Hoshide S., Kario K. (2021) Seasonal variation in blood pressure: current evidence and recommendations for hypertension management. Hypertens Res., 44(11): 1363–1372. doi: 10.1038/s41440-021-00732-z.
28. Stergiou G.S., Palatini P., Modesti P. et al. (2020) Seasonal variation in blood pressure: Evidence, consensus and recommendations for clinical practice. Consensus statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J. Hypertens., 38(7): 1235–1243. doi: 10.1097/HJH.0000000000002341.